Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NOX1 | Q9Y5S8 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | CYBB | P04839 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
| ▸ | NOX3 | Q9HBY0 | 1/20 | 0.33 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.33 |
| ▸ | MYLK | Q15746 | 1/20 | 0.33 |
| ▸ | TERT | O14746 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12180978 | 0.90 | MAPT (0.35) | NPC1GRM5GRM1POLBNOX1 | |
| SCHEMBL14750335 | 0.88 | BCHE (0.43) | NPC1GRM5GRM1NOX1MAPT | |
| SCHEMBL7436707 | 0.71 | GSK3B (0.43) | NPC1GRM5GRM1MAPTMEN1 | |
| SCHEMBL7439007 | 0.69 | ELANE (0.41) | NPC1MAPTMEN1KMT2ALMNA | |
| SCHEMBL28043394 | 0.66 | NPC1 (0.53) | NPC1POLBMAPTMEN1KMT2A | |
| SCHEMBL25214258 | 0.65 | CES2 (0.50) | NPC1POLBMAPTCES2CES1 | |
| SCHEMBL1488972 | 0.63 | BCHE (0.39) | POLBNOX1MAPTMEN1KMT2A | |
| SCHEMBL13431736 | 0.62 | NPC1 (0.53) | NPC1MAPTMEN1KMT2AGAA | |
| SCHEMBL9241143 | 0.62 | GRM1 (0.42) | GRM5GRM1BCHE | |
| Thianthrene SCHEMBL8504206 | 0.62 | NOX1 (0.56) | NOX1MAPTMEN1KMT2ACYBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | disclosed |
| CN-112755193-A | Method of treating malignancies with anti-tyrosine kinase inhibitors using dianhydrogalactitol or a derivative thereof | 德玛医药 | 2021-05-07 | — | — | CN | disclosed |
| EP-2872161-B1 | DIANHYDROGALACTITOL FOR USE IN TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS | DEL MAR PHARMACEUTICALS (CA) | 2020-12-16 | — | — | EP | disclosed |
| US-9212143-B2 | Small molecule inhibitors of protein kinases | LEVOLTA PHARMACEUTICALS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212143-B2 | Small molecule inhibitors of protein kinases | LEVOLTA PHARMACEUTICALS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212143-B2 | Small molecule inhibitors of protein kinases | LEVOLTA PHARMACEUTICALS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2015-07-02 | — | — | US | disclosed |
| EP-2872161-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | Del Mar Pharmaceuticals (CA) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014004376-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (CA) | 2014-01-03 | — | — | WO | disclosed |
| US-20130058980-A1 | SMALL MOLECULE INHIBITORS OF PROTEIN KINASES | LEVOLTA PHARMACEUTICALS, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130058980-A1 | SMALL MOLECULE INHIBITORS OF PROTEIN KINASES | LEVOLTA PHARMACEUTICALS, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130058980-A1 | SMALL MOLECULE INHIBITORS OF PROTEIN KINASES | LEVOLTA PHARMACEUTICALS, INC. | 2013-03-07 | — | — | US | disclosed |
| US-8389525-B2 | Small molecules for inhibition of protein kinases | LEVOLTA PHARMACEUTICALS, INC. | 2013-03-05 | — | — | US | disclosed |
| US-8389525-B2 | Small molecules for inhibition of protein kinases | LEVOLTA PHARMACEUTICALS, INC. | 2013-03-05 | — | — | US | disclosed |
| US-8389525-B2 | Small molecules for inhibition of protein kinases | LEVOLTA PHARMACEUTICALS, INC. | 2013-03-05 | — | — | US | disclosed |
| WO-2011139295-A1 | SMALL MOLECULE INHIBITORS OF PROTEIN KINASES | IMC BIOTECHNOLOGY, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011139295-A1 | SMALL MOLECULE INHIBITORS OF PROTEIN KINASES | IMC BIOTECHNOLOGY, INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20110275645-A1 | Small Molecules for Inhibition of Protein Kinases | LEVOLTA PHARMACEUTICALS, INC. | 2011-11-10 | — | — | US | disclosed |
| US-20110275645-A1 | Small Molecules for Inhibition of Protein Kinases | LEVOLTA PHARMACEUTICALS, INC. | 2011-11-10 | — | — | US | disclosed |
| US-20110275645-A1 | Small Molecules for Inhibition of Protein Kinases | LEVOLTA PHARMACEUTICALS, INC. | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | WHR1, AIPL1, TDP1 | NPC1 4189/4885GRM5 2764/4885GRM1 1977/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | NPC1 4268/4885GRM5 2357/4885GRM1 1653/4885 |
| US-20130058980-A1 | SMALL MOLECULE INHIBITORS OF PROTEIN KINASES | SYK, BTK, LCK | NPC1 4393/4885GRM5 3695/4885GRM1 3094/4885 |
| US-20110275645-A1 | Small Molecules for Inhibition of Protein Kinases | MAP3K1, MAP3K20, MAP3K6 | NPC1 2665/4885GRM5 3060/4885GRM1 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.